Tobramycin

Aminoglycoside antibiotic capable of translational readthrough

Phase of research

FDA-/EMA-approved for Cystic Fibrosis

How it helps

Anti-Infective,Restore CFTR Function

General information

N/A

Synonyms

N/A

Marketed as

Dietary sources

N/A

Structure not available

C18H37N5O9

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
F508del
1 3.06
Link Tested on Impact factor Notes
Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation human cell cultures 3.06 Co-treatment with mannitol is not more effective
G542X
1 3.30
Link Tested on Impact factor Notes
Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. mice 3.30
General effect
2 3.19
Link Tested on Impact factor Notes
Arikace compared to TOBI® in people with CF with chronic Pseudomonas aeruginosa infections (Insmed TR02-108) humans N/A More effective than Amikacin.
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. humans 3.19 Tobramycin inhalation powder is more convenient than tobramycin inhalation solution.

Does not treat

Mutation Number of sources Average impact factor